Two New Treatments for Gonorrhea; one is available now!

In this episode of the Conversations with CEI, infectious disease specialist Dr. Steven Fine delves into groundbreaking advancements in the treatment of urogenital gonorrhea. The episode highlights the FDA's December 2025 approval of two innovative oral therapies that mark a significant step forward in combating this prevalent sexually transmitted infection.

Dr. Fine discusses the first of these treatments, Zoliflodacin (Nuzolvence), a novel medication specifically developed for urogenital gonorrhea. Administered as a single oral dose, it offers patients a convenient and effective option. The second treatment, Gepotidacin (Blujepa), is a versatile drug initially approved in March 2025 for urinary tract infections (UTIs). Now, it has been authorized for urogenital gonorrhea treatment, requiring two oral doses for optimal efficacy.

Throughout the episode, Dr. Fine provides insights into the clinical trials, mechanisms of action, and potential impact of these therapies on public health. He also emphasizes the importance of addressing antibiotic resistance in gonorrhea and how these new treatments may help mitigate this growing concern.

For more information, listeners can refer to the FDA's official announcement and other resources provided below.

Tune in to this episode to learn more about these exciting developments and their implications for the future of infectious disease treatment. Related Content:

FDA Approves Two Oral Therapies to Treat Gonorrhea https://www.fda.gov/news-events/press-announcements/fda-approves-two-oral-therapies-treat- gonorrhea
CEI Clinical Consultation Line 1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health.
https://ceitraining.org/

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(63)

It’s Complicated…but Necessary! Navigating Confidential Sexual Healthcare for Adolescents

“Nobody goes into adolescent medicine or into a field of medicine that serves adolescent patients because it’s simple and straightforward, right?” In May 2024, the New York State Department of Health ...

11 Heinä 202422min

Special Conversations with CEI: Best Practices for Hepatitis C and Pregnancy Screening: Advice from a Fellow Clinician

Hepatitis C virus (HCV) is a pathogen spread by contact with blood from a person with HCV infection. Prevalence among the US obstetric population rose nearly 10-fold over the past 20 years and approxi...

13 Kesä 202434min

Special Conversations with CEI: Best Practices for Working with People Who Use Substances

6 Kesä 202430min

Special Conversations with CEI: The Impact of Hepatitis C Screening during Pregnancy: A Client’s Story

30 Touko 202436min

Would you consider Injectable ART for those unable to suppress with oral HIV treatment?

In this episode, Dr. Steven Fine discusses some of the latest data that might be used to support starting patients who are unable to take oral antiretroviral medications on long acting, injectable ARV...

7 Touko 202414min

HIV Prevention Research in the Kink-Involved Population

Cultural humility in healthcare, especially for those involved in kink, requires going beyond basic competence. Clinicians must provide respectful care, acknowledging patients' diverse backgrounds and...

11 Huhti 202423min

Doxy-PEP Part II: Where Are We Now?

In this episode, Dr. Marguerite Urban and Dr. Daniela DiMarco pick up from the November 2023 episode of Conversations with CEI, where they talked about Doxy-PEP for the prevention of sexually transmit...

14 Maalis 202417min

Tackling Stigma with Compassion: Harm Reduction in Clinical Practice

Harm reduction is a set of practical strategies and ideas aimed at reducing negative consequences associated with drug use. It is also a movement for social justice build on a belief in, and respect f...

8 Helmi 202428min